VYGR

1.5304.97%
AW

Alfred W. Sandrock

CEO & Director

Dr. Alfred W. Sandrock Jr., also known as Al, M.D., Ph.D., is Director of FORUM Pharmaceuticals Inc. from May 2012. Dr. Sandrock joined the FORUM Pharmaceuticals Inc. in May 2012. Dr. Sandrock is CEO & Director of Voyager Therapeutics, Inc. from March 22, 2022 and was its President since March 22, 2022 until October 20, 2026. Dr. Sandrock was Director of Voyager Therapeutics, Inc. from February 07, 2022 to March 22, 2022. Dr. Sandrock is Chief Medical Officer and Group Senior Vice President of Biogen Idec Ltd. Dr. Sandrock joined the Biogen Idec Ltd. in May 2013. Dr. Sandrock is Director of Verge Analytics, Inc. from February 2022. Dr. Sandrock is Member of Strategic Advisory Board of Longwood Fund. Dr. Sandrock is Independent Director of Transition Bio, Inc. from 2022. Dr. Sandrock is Advisory Board Members of T.Rx Capital LLC. Dr. Sandrock was Independent Director of Neurocrine Biosciences, Inc. from September 2015 to May 19, 2020. Dr. Sandrock was employed at Neurocrine Biosciences, Inc. from September 03, 2015 to May 19, 2020. Dr. Sandrock was Head of Research & Development of Biogen Inc. until December 31, 2021. Dr. Sandrock was Executive Vice President of Research & Development of Biogen Inc. from January 27, 2020. Dr. Sandrock was Executive VP of Research & Development and Chief Medical Officer of Biogen Inc. from October 01, 2019 to January 27, 2020. Dr. Sandrock was Executive VP & Chief Medical Officer of Biogen Inc. from October 2017 to October 01, 2019. Dr. Sandrock was employed at Biogen Inc. from 1998 to December 31, 2021. Dr. Sandrock was Member of Scientific Advisory Board of Flex Pharma, Inc. Dr. Sandrock joined the Flex Pharma, Inc. in June 2015. Dr. Sandrock was Director of Disarm Therapeutics, Inc. until October 2020. Dr. Sandrock was Director & Member of Scientific Advisory Board of Disarm Therapeutics, Inc. Dr. Sandrock was employed at Disarm Therapeutics, Inc. until October 2020. Dr. Sandrock was Member of Scientific Advisory Board of Camp4 Therapeutics Corporation from March 2022. Dr. Sandrock was Director of Atalanta Therapeutics, Inc. from March 2022 to September 2024. Dr. Sandrock was employed at Atalanta Therapeutics, Inc. until September 2024. Dr. Sandrock has Ph.D. in Neurobiology from Harvard University, B.A. in Human Biology from Stanford University, M.D. in Neurobiology from Harvard Medical School.

Positions